Welcome to our dedicated page for Cellectis news (Ticker: CLLS), a resource for investors and traders seeking the latest updates and insights on Cellectis stock.
About Cellectis
Cellectis (NASDAQ: CLLS) is a clinical-stage biopharmaceutical company at the forefront of gene-editing technologies, dedicated to developing innovative cancer immunotherapies and other therapeutic solutions. Leveraging over 18 years of expertise in genome engineering, Cellectis has established itself as a pioneer in the field, utilizing its proprietary TALEN® (Transcription Activator-Like Effector Nucleases) technology and PulseAgile electroporation system to create precise, next-generation therapies. These tools enable the company to harness the immune system's power to target and eliminate cancer cells effectively.
Core Focus: Allogeneic CAR-T and Gene-Edited HSPCs
Cellectis specializes in developing allogeneic Chimeric Antigen Receptor T-cells (UCART) for immuno-oncology applications. Unlike traditional autologous CAR-T therapies, which require harvesting and engineering a patient’s own cells, Cellectis’s allogeneic approach uses gene-edited donor cells. This innovation offers scalability, reduced manufacturing costs, and faster availability, making it a game-changer in cancer treatment. Additionally, the company is advancing gene-edited hematopoietic stem and progenitor cells (HSPCs) for therapeutic indications beyond oncology, showcasing its versatility in genome editing.
Proprietary Technologies
Cellectis’s competitive edge lies in its proprietary technologies:
- TALEN® Technology: A precise and versatile gene-editing tool that enables targeted modifications to DNA, ensuring high specificity and minimal off-target effects.
- PulseAgile Electroporation System: A cutting-edge delivery platform that enhances the efficiency of introducing genetic material into cells.
These technologies form the backbone of Cellectis’s product pipeline, enabling the development of innovative therapies that address unmet medical needs.
Market Position and Industry Context
Cellectis operates within the rapidly growing fields of immuno-oncology and precision medicine. The global demand for effective cancer therapies continues to rise, driven by advancements in biotechnology and an increasing understanding of the immune system's role in combating diseases. As a clinical-stage company, Cellectis focuses on research and development, with a pipeline of promising product candidates undergoing rigorous clinical trials. However, this stage also presents challenges, including regulatory approvals, high R&D costs, and competition from other biotech firms specializing in gene editing and CAR-T therapies.
Competitive Landscape
Key competitors in the gene-editing and CAR-T therapy space include CRISPR Therapeutics, Editas Medicine, and Intellia Therapeutics. Cellectis differentiates itself through its allogeneic approach, which offers significant advantages in scalability and cost-effectiveness. By addressing the limitations of autologous therapies, such as manufacturing complexity and patient-specific variability, Cellectis positions itself as a leader in next-generation cancer immunotherapies.
Challenges and Opportunities
While Cellectis’s innovative approach holds immense promise, the company faces several challenges. These include navigating a complex regulatory environment, managing high development costs, and competing in a crowded market. However, the potential rewards are substantial, with successful therapies offering transformative benefits for patients and significant market opportunities. The company’s focus on leveraging proprietary technologies and addressing unmet medical needs positions it well for long-term success.
Conclusion
Cellectis is a trailblazer in the biopharmaceutical industry, combining cutting-edge gene-editing technologies with a commitment to innovation in cancer immunotherapy and beyond. By leveraging its proprietary TALEN® technology and allogeneic approach, the company aims to revolutionize the treatment landscape, offering scalable, cost-effective solutions to some of the most pressing medical challenges. As a clinical-stage entity, Cellectis represents a high-risk, high-reward opportunity within the dynamic biotechnology sector.
Cellectis announced pre-clinical data presentation at SITC's 39th Annual Meeting, showcasing strategies to enhance CAR T-cell efficacy against solid tumors. The research focuses on overcoming challenges in the tumor microenvironment (TME) using TALEN®-mediated gene editing to generate allogeneic CAR T-cells. The company developed two key approaches: a FAP-dependent expression system to limit cytotoxic activity to tumor areas, and integration of IL-12 into PD-1 regulatory elements while inactivating TGFBR2. These strategies showed enhanced T-cell proliferation and infiltration while reducing tumor burden and limiting side effects, potentially offering new therapeutic options for solid tumor patients.
Cellectis (CLLS) reported Q3 2024 business updates and financial results, highlighting ongoing enrollment in UCART22 and UCART20x22 clinical trials, with Phase 1 dataset expected in 2025. The company's cash position stands at $264 million as of September 30, 2024, projecting runway into 2027. Research and development activities have commenced on three programs under the AstraZeneca partnership. The company reported revenues of $34.1 million for the nine months ended September 30, 2024, compared to $7.2 million in the same period of 2023. Net loss was $42.7 million, an improvement from the $59.3 million loss in the previous year.
Cellectis (NASDAQ: CLLS), a clinical-stage biotechnology company focused on gene-editing and cell therapies, has announced it will release its third quarter 2024 financial results on November 4, 2024 after US market close. The company will host an investor conference call and webcast on November 5, 2024 at 8:00 AM ET / 2:00 PM CET to discuss the quarterly results and provide a business update.
Cellectis, a clinical-stage biotechnology company, will present pre-clinical data on TALE base editors (TALEB) and non-viral gene insertion at the European Society of Cell and Gene Therapy 31st annual congress in Roma, Italy, from October 22-25, 2024. Two posters will be showcased:
1. 'Controlling C-to-T editing with TALE base editors' by Alexandre Juillerat, Ph.D., on October 24. This study enhances understanding of TALEB and allows for the design of efficient and specific tools potentially compatible with therapeutic applications.
2. 'Circular Single-Stranded DNA Enables Efficient TALEN-Mediated Gene Insertion in Long Term HSC' by Julien Valton, Ph.D., also on October 24. This research demonstrates that circularizing ssDNA increases gene insertion rates in long-term HSCs and may enhance their engraftment capacity in preclinical murine models, advancing non-viral gene therapy.
Cellectis (CLLS) has released its monthly information on share capital and voting rights as of September 30, 2024. The company reported a total of 100,093,873 shares in the capital and 88,569,683 voting rights. This information is disclosed in compliance with Article 223-16 of the General Regulation of the French financial markets authority.
Cellectis is listed on the Euronext Growth market with the ISIN code FR0010425595. For additional information, investors and media can contact the company's designated representatives, including the Director of Communications and the Chief of Staff to the CEO. The Interim Chief Financial Officer is available for investor relations inquiries.
Cellectis (CLLS) has released its monthly update on share capital and voting rights as of August 31, 2024. The company reported a total of 100,093,635 shares in the capital and 88,029,440 voting rights. This information is disclosed in compliance with Article 223-16 of the General Regulation of the French financial markets authority. Cellectis is listed on the Euronext Growth market under the ISIN code FR0010425595.
For investors seeking further information, Cellectis has provided contact details for media and investor relations inquiries. This regular disclosure helps maintain transparency and keeps shareholders informed about the company's capital structure.
Cellectis, a clinical-stage biotechnology company, has published a scientific article in Science Advances showcasing promising pre-clinical results for treating triple-negative breast cancer (TNBC) using TALEN®-edited MUC1 CAR T-cells. The study demonstrates that multi-armored CAR T-cells, engineered with PD1KO, tumor-specific IL12 release, and TGFBR2KO attributes, showed enhanced cytotoxic activity against TNBC in mouse models.
Notably, intratumoral treatment effectively reduced both local and distant tumors using low doses of the engineered CAR T-cells, suggesting potential efficacy against metastasis. The research highlights the capabilities of multiplex editing in improving both efficacy and safety of CAR T-cell therapies for solid tumors, offering hope for advanced-stage TNBC patients with treatment options.
Cellectis (NASDAQ: CLLS) has published an article in Molecular Therapy showcasing their innovative SMART DUAL CAR T-cell approach for treating solid tumors. Using TALEN® gene editing technology, Cellectis has developed allogeneic CAR T-cells that express:
1. A constitutive CAR targeting FAP+ cancer-associated fibroblasts (CAFs) in solid tumors
2. An inducible CAR, expressed only in the presence of FAP+ CAFs, targeting mesothelin
This strategy aims to overcome challenges in solid tumor treatment, including low T-cell infiltration, immunosuppressive microenvironment, and on-target off-tumor toxicity. In mice models, these SMART Dual CAR T-cells efficiently infiltrated and targeted triple-negative breast tumors without observable off-tumor toxicity.
Cellectis (NASDAQ: CLLS), a clinical-stage biotechnology company focused on gene-editing and cell therapies, has appointed Dr. Adrian Kilcoyne as its new Chief Medical Officer. Dr. Kilcoyne brings extensive experience in oncology and cell therapy from his previous roles at Celularity, Humanigen, AstraZeneca, and Celgene. His appointment is expected to strengthen Cellectis' clinical development efforts in advancing their pipeline of next-generation CAR T-cell therapies.
Dr. Kilcoyne's background includes a medical degree from Trinity College, Dublin, training in Gynecological Oncology and Public Health Medicine, and an MBA. He replaces Dr. Mark Frattini, who is departing to pursue other opportunities. The company's CEO, André Choulika, expressed confidence in Dr. Kilcoyne's ability to contribute to Cellectis' mission of providing transformative UCART therapies to patients with significant unmet medical needs.
Cellectis provided its financial results for Q2 2024, reporting a cash position of $273 million as of June 30, 2024, and a cash runway projection into 2026. Key highlights include:
Pipeline Updates: UCART22 received ODD from both the FDA and the European Commission for ALL treatment, and RPDD from the FDA. CLLS52 (alemtuzumab) also received ODD from the FDA for ALL treatment.
Financial Performance: Consolidated revenues and other income increased to $16 million for the six months ended June 30, 2024, compared to $5.6 million for the same period in 2023. Consolidated net loss reduced to $19.6 million from $41.8 million, reflecting better financial management and increased revenues.
Partnerships: Cellectis announced a $140 million investment from AstraZeneca, which now owns approximately 44% of Cellectis' share capital.
Research: A significant publication in Nature Communications on their non-viral gene therapy approach for SCD.
FAQ
What is the current stock price of Cellectis (CLLS)?
What is the market cap of Cellectis (CLLS)?
What does Cellectis specialize in?
How does Cellectis differentiate from competitors?
What are Cellectis’s proprietary technologies?
What challenges does Cellectis face?
What is the significance of allogeneic CAR-T therapies?
What market does Cellectis target?
Who are Cellectis’s main competitors?
What stage of development is Cellectis in?
